Drug Development
Killing the malaria parasite by blocking its recycling system
A new drug candidate stops the malaria parasite breaking down waste, resulting in a fatal ‘molecular constipation', finds University of Melbourne-led study.
Starving the bacterium that causes pneumonia
By targeting an essential nutrition pathway, University of Melbourne researchers hope to develop drug targets against the bacteria that cause pneumonia
New drug target for sugar-coated viruses
New research including University of Melbourne shows targeting sugar production in human cells has potential for broad-spectrum drugs against viruses.
New targets for epilepsy treatment
Associate Professor Reid is developing new drugs for epilepsy, with the view of treating a larger population of people with epilepsy.
Why are there so few drugs to treat viruses?
As coronavirus case numbers surge, University of Melbourne experts explain why we have effective drugs for bacterial diseases, but relatively few for viruses.
Sea snail venom holds clues for diabetes treatment
A new study, that the University of Melbourne is part of, finds modified human insulin that mimics fast-acting sea snail venom is a potential diabetes treatment
Lessons for a future pandemic
Professor Peter Doherty from the University of Melbourne discusses the latest COVID-19 drug and vaccine research, and how best to prepare for future pandemic
Double hit to malaria from new drug candidate
New antimalarial compounds target two molecules involved in critical stages of the parasite’s life cycle, finds new research including University of Melbourne.
Curbing cancer’s addiction to treat it
Most cancers need a specific molecule to grow and spread; cutting off the supply is showing promise as a way to treat it, finds University of Melbourne research
Science, society and drug design
After being the first in his family to go to university, biochemist Sir Thomas Blundell has worked in music, local council, medical research and advisor to a PM